



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/552,598	10/07/2005	Russell L. Kreeger	62732A	2419
35503	7590	12/23/2009	EXAMINER	
Union Carbide Chemicals and Plastics Technology Corporation P.O. Box 1967 Midland, MI 48641-1967			WHITE, EVERETT NMN	
			ART UNIT	PAPER NUMBER
			1623	
			MAIL DATE	DELIVERY MODE
			12/23/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)	
	10/552,598	KREEGER ET AL.	
	Examiner	Art Unit	
	EVERETT WHITE	1623	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 03 December 2009.
 2a) This action is **FINAL**. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1,3-11,13 and 19 is/are pending in the application.
 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) 1,3-11,13 and 19 is/are rejected.
 7) Claim(s) _____ is/are objected to.
 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. _____ .
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)	5) <input type="checkbox"/> Notice of Informal Patent Application
Paper No(s)/Mail Date _____.	6) <input type="checkbox"/> Other: _____ .

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on December 3, 2009 has been entered.

2. The amendment filed December 3, 2009 has been received, entered and carefully considered. The amendment affects the instant application accordingly:
 - (A) Claims 2, 12 and 14-18 have been canceled;
 - (B) New Claim 19 has been added;
 - (C) Claims 1, 3 and 4 have been amended;
 - (D) Comments regarding Office Action have been provided drawn to:
 - (I) 103(a) rejection, which is maintained for the reasons of record.

3. Claims 1, 3-11, 13 and 19 are pending in the case.

Claim Objections

4. Claim 1 is objected to because of the following informalities: In Claim 1, line 6, formula II which is disclosed as “[R⁵R⁶R⁷R^BIC⁺] (A^z)_{1/z}” in the set of claims filed December 3, 2009 appears to be a typing error and should be corrected to read as -- [R⁵R⁶R⁷R⁸N⁺] (A^z)_{1/z} -- as disclosed in the original claims. Appropriate correction is required.

Claim Rejections - 35 USC § 103

5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and

the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.


This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.


6. Claims 1, 3-11 and 13 stand rejected under 35 U.S.C. 103(a) as being unpatentable over Brode et al (US Patent No. 5,407,919) for the reasons disclosed below.

Applicants claim a hydroxyethyl cellulose ether having from 4,000 to 10,000 anhydroglucose repeat units and being substituted with (a) on the average from 0.0003 to 0.08 moles, per mole of anhydroglucose unit, of a substituent comprising an alkyl or arylalkyl group having from 8 to 24 carbon atoms and (b) a substituent having the formula II




wherein R⁵, R⁶ and R⁷ each independently are -CH₃ or -C₂H₅, R⁸ is -CH₂-CHOH-CH₂- or -CH₂CH₂-; A^{z-} is an anion, and z is 1, 2 or 3. Applicants also claim personal care composition comprising the cellulose ether of Claim 1.

The Brode et al patent discloses cellulose ethers substituted with a cationic substituent and a hydrophobic substituent, which provide enhanced properties when used in personal care compositions (see abstract). The Brode et al patent discloses that the cellulose ethers thereof, which includes hydroxyethyl cellulose (see column 2, line 20), as having a molecular weight ranging from about 10,000 to 500,000 grams per gram mole (see column 2, lines 25-27), and as having a viscosity that ranges from about 5 to 5,000 centipoise (see column 2, lines 36-37). These above mentioned properties of cellulose ether embraces the hydroxyethyl cellulose, number of anhydroglucose repeating units, viscosity measurement and personal care composition disclosed in instant Claims 1, 6 and 11. The Brode et al patent describes a preferred hydrophobic substituents as having the formula:



wherein each of R_1 and R_2 are $-CH_3$ or C_2H_5 ; R_3 is $CH_2 CHOCH_2$; R_4 is an alkyl or arylalkyl group having about 8 to 18 carbon atoms; and A_1 is a halide ion (see column 2, line 66 to column 3, line 17), which cover the formula requirement described for substituent (a) in instant Claims 1, 7 and 11. The Brode et al patent also describes other hydrophobic substituents that may be used which include those prepared from hydrophobic containing reagents such as glycidyl ethers, e.g., nonylphenylglycidyl ether or dodecylphenyl glycidyl ether, or alpha-olefin epoxides, e.g., 1,2 epoxy hexadecane and there respective chlorohydrins, or alkyl halides, e.g., dodecylbromide, and mixtures thereof, which covers the substituent of step (a) of instant Claim 1 and the description recited for substituent (a) in instant Claims 8-10. The Brode et al patent discloses cationic substituents used in their invention that have the formula:



wherein each of R⁵, R⁶ and R⁷ is CH₃ or C₂H₅, R⁸ is CH₂CHOHCH₂ or CH₂CH₂; and A₂ is a halide ion (see column 3, lines 37-55). The description of the cationic substituents of the Brode et al patent covers the substituent (b) of formula II of instant Claims 1 and 11. See column 3, lines 61-63 of the Brode et al patent wherein the substitution level of the cationic substituent ranges from about 0.05 to 0.5 gram moles of cationic substituent per gram mole of cellulose ether, which covers part the amount of moles for substituent (b) of instant Claims 5 and 11.

The instantly claimed cellulose ether differs from the cellulose ethers of the Brode et al patent by claiming that the substituent (a) is substituted on the average from 0.0003 to 0.08 moles per mole of anhydroglucose unit, wherein the structurally similar hydrophobic group of the Brode et al patent is greater than 0.11 gram moles per gram mole of cellulose ether.

It is noted that the cellulose ethers of the Brode et al patent are used in personal care compositions, including skin creams, lotions, soaps, shampoos, conditions and the like (see column 4, lines 50-55). Applicants are reminded that molar proportions or ranges of molecular weight cannot be the basis for patentability of subject matter encompassed by the prior art where there is nothing to indicate such proportion or range is critical. *In re Hoeschele* (CCPA 1969) 406 F2d 1403, 160 USPQ 809; *In re Cole* (CCPA 1964) 326 F2d 769, 140 USPQ 230. It is well within the skill of technicians of the instant art to decrease the viscosity of personal care compositions to obtain a desired thickness of the product.

One having ordinary skill in the art would have been motivated to employ the process of the prior art with the expectation of obtaining the desired product because the skilled artisan would have expected the analogous starting materials to react similarly.

Accordingly, it would have been obvious to one of ordinary skill in the art at the time of Applicants invention to adjust the viscosity of the cellulose ether of the Brode et al patent by decreasing the amount of the hydrophobic substituent in view of their closely related structures and the resulting expectation of similar cleaning properties.

7. Applicant's arguments filed December 13, 2009 have been fully considered but they are not persuasive. Applicants argue against the rejection on the ground that no motivation to reduce cationic substitution from the Brode teaching has been established. This argument is not persuasive since the Brode et al patent discloses the substitution level of the cationic substituent that ranges from about 0.05 to 0.5 gram moles of cationic substituent per gram mole of cellulose ether (see column 3, lines 61-63), which covers the substitution level recited in instant Claim 5 which discloses the cellulose ether comprising on the average from 0.1 to 0.6 moles of the substituent (b) per mole of anhydroglucose unit. Accordingly, the rejection of Claims 1, 3-11 and 13 under 35 U.S.C. 103(a) as being unpatentable over the Brode et al patent is maintained for the reasons of record.

8. Claims 1, 3 and 11 stand rejected under 35 U.S.C. 103(a) as being unpatentable over Brode et al (US Patent No. 5,407,919) as applied to Claims 1 and 13 above, and further in view of Partain III et al (US Patent No. 6,372,901).

The information with regard to the rejection of the instantly claimed cellulose ether and process of preparation provided above in the Brode et al patent is incorporated into the current rejection.

Claims 1, 3 and 11 of the instant invention differ from the Brode et al patent by claiming that the cellulose ether thereof, which may be a hydroxyethyl cellulose, comprises on the average 1.0 to 3.0 moles or 1.5 to 2.5 moles of hydroxyethyl groups per mole of anhydroglucose unit.

The Partain et al patent, which discloses polysaccharides with alkyl-aryl hydrophobic groups wherein the polysaccharide may be selected as hydroxyethyl cellulose (see title, column 4, lines 38, 39 and 43-45), shows that polysaccharides having a hydroxyethyl molar substitution (MS) of from about 1.5 to about 6 is well known in the art, which covers the molar substitution of the hydroxyethyl group recited in instant Claim 11.

One of ordinary skill in this art would have been motivated to combine the teaching of the Brode et al patent with the teaching of the Partain et al patent since both

patents disclose hydroxyethyl cellulose compositions that modify the rheology or stability of compositions.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to use the hydroxyethyl cellulose compounds of the Brode et al patent that have hydroxyethyl MS of 1.5 or higher in view of the recognition in the art, as evidenced by the Partain et al patent, that hydroxyethyl cellulose compounds having such hydroxyethyl molar substitution help to provide polysaccharides with increased stability.

9. Applicant's arguments filed December 3, 2009 have been fully considered but they are not persuasive. The rejection of Claims 1, 3 and 11 under 35 U.S.C. 103(a) as being unpatentable over the Brode et al patent as applied to Claims 1 and 13 above, and further in view of the Partain III et al patent is maintained for the reasons of record.

New Ground of Rejection

10. Claim 19 is rejected under 35 U.S.C. 103(a) as being unpatentable over Brode et al (US Patent No. 5,407,919) as applied to Claims 1, 3-11 and 13 above, and further in view of LeGrow et al (US Patent No. 6,489,274 B1, newly cited).

Applicants claim a personal care composition of Claim 13, further comprising sunflower seed oil.

The information disclosed in the rejection of the instantly claimed hydroxyethyl cellulose ether provided above with regard to the Brode et al patent is incorporated into the current rejection.

The personal care compositions disclosed in the Brode et al patent does not disclose sunflower seed oil as a component of the composition.

However, the LeGrow et al patent discloses personal care compositions that comprises oils that are used as surfactants that are beneficial for skin feel properties, wherein the oil may be selected as sunflower seed oil (see column 4, line 45). The personal care composition also comprises a conditioning agent, which may be selected as quaternized ethyl cellulose ethers, which may be similar to the hydroxyethyl cellulose ether of the instant claims.

The present of the quaternized ethyl cellulose ethers in the personal care compositions of the LeGrow et al patent gives motivation for the combination of the LeGrow et al patent with the personal care compositions of the Brode et al patent which also comprises quaternized ethyl cellulose ethers in the personal care compositions thereof.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to incorporate into the personal care composition of the Brode et al patent an oil such as sunflower seed oil in view of the recognition in the art, as evidenced by the LeGrow et al patent, that oils such as sunflower seed oil provides beneficial skin feel properties to personal care compositions.

11. Applicant's arguments with respect to claim 19 have been considered but are moot in view of the new ground(s) of rejection.

Summary

12. All the pending claims (Claims 1, 3-11, 13 and 19) are rejected.

Examiner's Telephone Number, Fax Number, and Other Information

13. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Everett White whose telephone number is 571-272-0660. The examiner can normally be reached on 9:30 to 6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shaojia A. Jiang can be reached on 571-272-0627. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Everett White/
Examiner, Art Unit 1623

/Shaojia Anna Jiang/
Supervisory Patent Examiner, Art Unit 1623